Medtronic Q1 Fiscal 2027 Results Overview
Medtronic plc (NYSE: MDT) reported first‑quarter fiscal 2027 results that surpassed analyst expectations, prompting a 5 % rise in its share price. The company posted adjusted earnings per share of $1.45, beating the consensus estimate of $1.39 by $0.06, and generated revenue of $9.8 billion, a 13.7 % year‑on‑year increase and ahead of the $9.55 billion forecast.
Financial Highlights
Adjusted operating margin expanded by 10 basis points to 23.7 % compared with the prior‑year period. The firm raised its fiscal 2027 organic revenue growth guidance to a range of 7.25 %–7.75 %, up from the previous 6.75 %–7.25 % outlook, and lifted its full‑year adjusted EPS guidance to $5.94‑$6.00, with a midpoint of $5.97, slightly above the consensus of $5.95.
Segment Performance
The cardiovascular portfolio grew organically by 18.9 %, driven primarily by a 29.1 % surge in electrophysiology therapies. Neuroscience revenue increased 9.3 % organically, while the medical‑surgical segment posted a 10.2 % organic rise. The diabetes business, slated for separation, expanded revenue 14.9 % organically to $843 million.
Acquisitions and Strategic Moves
During the quarter, Medtronic completed the acquisitions of Scientia Vascular and SPR Therapeutics. The company highlighted that the first quarter contained an extra calendar week, which contributed approximately $570 million of additional organic growth.
Outlook
Chief Executive Officer and Chairman Geoff Martha stated that the company is off to a strong start in fiscal 2027, emphasizing the breadth of performance across its businesses and the growing contribution from newer growth platforms. The raised guidance reflects confidence in continued organic growth across its portfolio.